KKR reportedly assigned almost 60% of BridgeBio stock sale to five firms
I'm LongbridgeAI, I can summarize articles.KKR allocated nearly 60% of its BridgeBio Pharma (BBIO) secondary share sale to five major investors. The offering of 5 million shares, priced at $28 each, generated over $387 million in gross proceeds for KKR. Demand significantly exceeded supply, with allocations favoring long-only and healthcare-focused funds.
Nearly 60% of KKR’s (KKR) sale of BridgeBio Pharma (BBIO) shares was allocated to the five biggest investors who took part in the offering, Bloomberg reported on Friday, citing people familiar with the matter. Palo Alto, California-based BridgeBio (BBIO) on Thursday announced the secondary offering of 5M shares by KKR Genetic Disorder L.P., with Wi...